Calliditas Therapeutics AB Profit Margin

The latest profit margin for CALT is -30.0% as of June 2024. That compares with -25.42% in the prior-year period — down 18.0% year over year. That is below the Healthcare sector average of 13.76%. Investors often review this figure alongside Calliditas Therapeutics AB's historical trend and sector peers before judging valuation or financial health.

Over the past year, CALT's profit margin moved from -25.42% to -30.0% — a 18.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Calliditas Therapeutics AB's valuation or profitability profile.

Against Healthcare companies, CALT currently prints -30.0% for profit margin, while the sector average sits near 13.76%. That is roughly 318.0% below the sector mean. Large gaps often invite a closer look at Calliditas Therapeutics AB's growth, margins, and balance sheet.

Profit Margin shows how effectively Calliditas Therapeutics AB converts resources into returns. At -30.0%, CALT may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -25.42% in the prior-year period — down 18.0% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting CALT's profit margin (-30.0%), review year-over-year change from -25.42%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.